- Home>
- Specialties>
- Infectious Diseases>
- Editor's Picks
Infectious Diseases Editor's Picks
SUMMARY AND COMMENT
Can HPV Vaccination Combat Genital Warts?
- November 5, 2009
- Anna Wald, MD, MPH
- Women's Health
Yes — and the benefit extends beyond vaccinated women to their male sexual partners.
- Reviewing:
- Fairley CK et al. Sex Transm Infect 2009 Oct 16
SUMMARY AND COMMENT
Second-Regimen Failure and Mortality Risk
- November 9, 2009
- Keith Henry, MD
- HIV/AIDS Clinical Care
Although second-regimen failure and associated mortality declined significantly between 1996/1997 and 2005, the mortality risk remained high.
- Reviewing:
- Deeks SG et al. Clin Infect Dis 2009 Nov 15; 49:1582
SUMMARY AND COMMENT
Immune Activation Persists Despite Effective ARTFree
- November 9, 2009
- Helmut Albrecht, MD
- HIV/AIDS Clinical Care
In a cohort of HIV-positive patients, markers of immune activation remained elevated despite 6 years of effective antiretroviral therapy. Immune activation was associated with lower CD4-cell counts.
- Reviewing:
- French MA et al. J Infect Dis 2009 Oct 15; 200:1212
SUMMARY AND COMMENT
Viramidine vs. Ribavirin for Hepatitis C Infection
- November 6, 2009
- Atif Zaman, MD, MPH
- Gastroenterology
The ribavirin prodrug viramidine failed to demonstrate noninferiority to ribavirin in achieving sustained virologic response rates.
- Reviewing:
- Benhamou Y et al. Hepatology 2009 Sep; 50:717
SUMMARY AND COMMENT
Therapeutic HPV Vaccination for Preventing Progression of Vulvar Intraepithelial NeoplasiaFree
- November 4, 2009
- Anna Wald, MD, MPH
- Women's Health
Clinical responses were achieved in women with grade 3 VIN who were vaccinated against HPV-16 viral oncoproteins.
- Reviewing:
- Kenter GG et al. N Engl J Med 2009 Nov 5; 361:1838
SUMMARY AND COMMENT
Life Expectancy for HIV-Infected Patients in the U.S.
- November 2, 2009
- Sonia Nagy Chimienti, MD
- HIV/AIDS Clinical Care
Average life expectancy continues to improve, but disparities persist.
- Reviewing:
- Harrison KM et al. J Acquir Immune Defic Syndr 2009 Sep 2
SUMMARY AND COMMENT
Darunavir + Raltegravir + Etravirine = High Rate of Treatment Success
- November 2, 2009
- Paul E. Sax, MD
- HIV/AIDS Clinical Care
Ninety percent of highly treatment-experienced patients who received this combination achieved virologic suppression at week 24; results were sustained at week 48.
- Reviewing:
- Yazdanpanah Y et al. Clin Infect Dis 2009 Nov 1; 49:1441
SUMMARY AND COMMENT
Dose Reduction Curbs Efavirenz Toxicity
- November 2, 2009
- Abigail Zuger, MD
- HIV/AIDS Clinical Care
Reducing the daily dose of efavirenz to 400 mg or even lower may curb the drug's toxicity without decreasing its effectiveness in patients with high plasma levels.
- Reviewing:
- van Luin M et al. J Acquir Immune Defic Syndr 2009 Oct 1; 52:240
SUMMARY AND COMMENT
Cruise Ship Restrooms: An Exposé
- November 5, 2009
- Abigail Zuger, MD
- General Medicine
Some are very clean, but most are not . . . until an outbreak of gastroenteritis occurs.
- Reviewing:
- Carling PC et al. Clin Infect Dis 2009 Nov 1; 49:1312
SUMMARY AND COMMENT
Influence of HCV Infection on Mortality in HIV-Infected Patients
- November 9, 2009
- Rajesh T. Gandhi, MD
- HIV/AIDS Clinical Care
HCV infection is associated with increased overall mortality, but not with AIDS-defining events, in HIV-infected patients.
- Reviewing:
- Chen T-Y et al. Clin Infect Dis 2009 Nov 15; 49:1605
